SPRB Stock Analysis: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$44.74
1.59 (3.70%)
▲
5d:
+7.54%
30d:
-13.72%
90d:
-24.65%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 27.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 27.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$158.30
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$98.29
54.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $44.73, which is considered slightly low relative to its 30-day fair value range of $42.79 to $51.60. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.8) compared to its historical average (15.3). Remarkably, the market is currently pricing in an annual earnings decline of 27.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $40.33, while resistance sits at $46.27. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: SPRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $151.00 (+250.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $40.33, while resistance sits at $46.27. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: SPRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $151.00 (+250.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$42.79 -
$51.60
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 250.0% below Wall St target ($151.00)
Trading Range Analysis
30-Day Trading Range
$42.79 -
$51.60
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$40.33
Resistance Level
$46.27
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.84
Wall Street Target
$151.00
(+250.0%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-27.4% cheaper
PE vs Historical
5.8 vs 15.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-27.4%
(market-implied from PE analysis)
1-Year Target
$38.83
(-10%)
2-Year Target
$34.94
(-19%)
3-Year Target
$31.45
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→15)
$82.36
(+91%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.8 to 15.3
Stabilization Target:
$112.98
(+161.9%)
PE Expansion Potential:
+161.9%
Share & Embed Analysis
Last updated: August 04, 2026 9:51 AM ET
Data refreshes hourly during market hours. Next update: 10:51 AM
Data refreshes hourly during market hours. Next update: 10:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 46 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
